{"id":"https://openalex.org/W2055706334","doi":"https://doi.org/10.2174/1381612033453712","title":"Anticancer Antifolates: Current Status and Future Directions","display_name":"Anticancer Antifolates: Current Status and Future Directions","publication_year":2003,"publication_date":"2003-12-01","ids":{"openalex":"https://openalex.org/W2055706334","doi":"https://doi.org/10.2174/1381612033453712","mag":"2055706334","pmid":"https://pubmed.ncbi.nlm.nih.gov/14529544"},"language":"en","primary_location":{"id":"doi:10.2174/1381612033453712","doi":"https://doi.org/10.2174/1381612033453712","is_oa":false,"landing_page_url":"https://doi.org/10.2174/1381612033453712","pdf_url":null,"source":{"id":"https://openalex.org/S55674637","display_name":"Current Pharmaceutical Design","issn_l":"1381-6128","issn":["1381-6128","1873-4286"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","jufo-1","ki-jl-1","medline","norway-1","poland-70","russia-white-list-2","vabb-shw"],"host_organization":"https://openalex.org/P4310320079","host_organization_name":"Bentham Science Publishers","host_organization_lineage":["https://openalex.org/P4310320079"],"host_organization_lineage_names":["Bentham Science Publishers"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Current Pharmaceutical Design","raw_type":"journal-article"},"volume":null,"type":"article","indexed_in":["crossref","pubmed"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5091214681","display_name":"John J. McGuire","orcid":"https://orcid.org/0000-0003-0302-3884","observed_orcids":["https://orcid.org/0000-0003-0302-3884"]},"institutions":[{"id":"https://openalex.org/I1292894508","display_name":"Roswell Park Comprehensive Cancer Center","ror":"https://ror.org/0499dwk57","country_code":"US","type":"facility","lineage":["https://openalex.org/I1292894508"]}],"countries":["US"],"is_corresponding":true,"raw_author_name":"John McGuire","raw_affiliation_strings":["Grace Cancer Drug Center, Roswell Park Cancer Institute, Buffalo, NY 14263, USA. John.McGuire@RoswellPark.edu","Grace Cancer Drug Center, Roswell Park Cancer Inst., Buffalo, NY 14263, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Grace Cancer Drug Center, Roswell Park Cancer Institute, Buffalo, NY 14263, USA. John.McGuire@RoswellPark.edu","institution_ids":["https://openalex.org/I1292894508"]},{"raw_affiliation_string":"Grace Cancer Drug Center, Roswell Park Cancer Inst., Buffalo, NY 14263, USA","institution_ids":["https://openalex.org/I1292894508"]}]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":1,"corresponding_author_ids":["https://openalex.org/A5091214681"],"corresponding_institution_ids":["https://openalex.org/I1292894508"],"apc_list":null,"apc_paid":null,"fwci":9.1728,"has_fulltext":false,"cited_by_count":305,"citation_normalized_percentile":{"value":0.99152766,"is_in_top_1_percent":true,"is_in_top_10_percent":true},"cited_by_percentile_year":{"min":96,"max":100},"biblio":{"volume":"9","issue":"31","first_page":"2593","last_page":"2613"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10274","display_name":"Heterocyclic Compound Synthesis and Bioactivity","score":0.3878999948501587,"subfield":{"id":"https://openalex.org/subfields/1605","display_name":"Organic Chemistry"},"field":{"id":"https://openalex.org/fields/16","display_name":"Chemistry"},"domain":{"id":"https://openalex.org/domains/3","display_name":"Physical Sciences"}},"topics":[{"id":"https://openalex.org/T10274","display_name":"Heterocyclic Compound Synthesis and Bioactivity","score":0.3878999948501587,"subfield":{"id":"https://openalex.org/subfields/1605","display_name":"Organic Chemistry"},"field":{"id":"https://openalex.org/fields/16","display_name":"Chemistry"},"domain":{"id":"https://openalex.org/domains/3","display_name":"Physical Sciences"}},{"id":"https://openalex.org/T11845","display_name":"Cancer therapeutics and mechanisms","score":0.20919999480247498,"subfield":{"id":"https://openalex.org/subfields/1312","display_name":"Molecular Biology"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T10499","display_name":"Folate and B Vitamins Research","score":0.11800000071525574,"subfield":{"id":"https://openalex.org/subfields/2916","display_name":"Nutrition and Dietetics"},"field":{"id":"https://openalex.org/fields/29","display_name":"Nursing"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/antifolate-drugs","display_name":"antifolate","score":0.9660000205039978},{"id":"https://openalex.org/keywords/methotrexate","display_name":"methotrexate","score":0.9760000109672546},{"id":"https://openalex.org/keywords/dihydrofolate-reductase-inhibitors","display_name":"dihydrofolate reductase inhibitors","score":0.9340000152587891},{"id":"https://openalex.org/keywords/thymidylate-synthase-inhibitors","display_name":"thymidylate synthase inhibitors","score":0.9869999885559082},{"id":"https://openalex.org/keywords/antifolate-resistance","display_name":"antifolate resistance","score":0.44600000977516174},{"id":"https://openalex.org/keywords/structure-based-drug-design","display_name":"structure-based drug design","score":0.5419999957084656}],"concepts":[{"id":"https://openalex.org/C2781382166","wikidata":"https://www.wikidata.org/wiki/Q50573407","display_name":"Antifolate","level":4,"score":0.9731616377830505},{"id":"https://openalex.org/C2781320022","wikidata":"https://www.wikidata.org/wiki/Q417149","display_name":"Dihydrofolate reductase","level":3,"score":0.8882664442062378},{"id":"https://openalex.org/C2778397455","wikidata":"https://www.wikidata.org/wiki/Q50429865","display_name":"Antimetabolite","level":3,"score":0.8122282028198242},{"id":"https://openalex.org/C2778685788","wikidata":"https://www.wikidata.org/wiki/Q415734","display_name":"Aminopterin","level":3,"score":0.7695250511169434},{"id":"https://openalex.org/C2781059491","wikidata":"https://www.wikidata.org/wiki/Q422232","display_name":"Methotrexate","level":2,"score":0.6867841482162476},{"id":"https://openalex.org/C98274493","wikidata":"https://www.wikidata.org/wiki/Q128406","display_name":"Pharmacology","level":1,"score":0.5113818049430847},{"id":"https://openalex.org/C185592680","wikidata":"https://www.wikidata.org/wiki/Q2329","display_name":"Chemistry","level":0,"score":0.4792247414588928},{"id":"https://openalex.org/C55493867","wikidata":"https://www.wikidata.org/wiki/Q7094","display_name":"Biochemistry","level":1,"score":0.4509356915950775},{"id":"https://openalex.org/C109246011","wikidata":"https://www.wikidata.org/wiki/Q6593447","display_name":"Purine analogue","level":4,"score":0.4426339268684387},{"id":"https://openalex.org/C109316439","wikidata":"https://www.wikidata.org/wiki/Q246181","display_name":"Cytotoxicity","level":3,"score":0.4320053458213806},{"id":"https://openalex.org/C123321153","wikidata":"https://www.wikidata.org/wiki/Q22676802","display_name":"Thymidylate synthase","level":4,"score":0.4143766760826111},{"id":"https://openalex.org/C2776476023","wikidata":"https://www.wikidata.org/wiki/Q188261","display_name":"Purine","level":3,"score":0.396503746509552},{"id":"https://openalex.org/C181199279","wikidata":"https://www.wikidata.org/wiki/Q8047","display_name":"Enzyme","level":2,"score":0.3116602897644043},{"id":"https://openalex.org/C86803240","wikidata":"https://www.wikidata.org/wiki/Q420","display_name":"Biology","level":0,"score":0.3023476302623749},{"id":"https://openalex.org/C202751555","wikidata":"https://www.wikidata.org/wiki/Q221681","display_name":"In vitro","level":2,"score":0.20986521244049072},{"id":"https://openalex.org/C2776694085","wikidata":"https://www.wikidata.org/wiki/Q974135","display_name":"Chemotherapy","level":2,"score":0.20621511340141296},{"id":"https://openalex.org/C203014093","wikidata":"https://www.wikidata.org/wiki/Q101929","display_name":"Immunology","level":1,"score":0.09276524186134338},{"id":"https://openalex.org/C2780456651","wikidata":"https://www.wikidata.org/wiki/Q238512","display_name":"Fluorouracil","level":3,"score":0.07851696014404297},{"id":"https://openalex.org/C54355233","wikidata":"https://www.wikidata.org/wiki/Q7162","display_name":"Genetics","level":1,"score":0.0}],"mesh":[{"descriptor_ui":"D000964","descriptor_name":"Antimetabolites, Antineoplastic","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":false},{"descriptor_ui":"D000964","descriptor_name":"Antimetabolites, Antineoplastic","qualifier_ui":"Q000737","qualifier_name":"chemistry","is_major_topic":true},{"descriptor_ui":"D005493","descriptor_name":"Folic Acid Antagonists","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":false},{"descriptor_ui":"D005493","descriptor_name":"Folic Acid Antagonists","qualifier_ui":"Q000737","qualifier_name":"chemistry","is_major_topic":true},{"descriptor_ui":"D006801","descriptor_name":"Humans","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D009369","descriptor_name":"Neoplasms","qualifier_ui":"Q000188","qualifier_name":"drug therapy","is_major_topic":false},{"descriptor_ui":"D011687","descriptor_name":"Purines","qualifier_ui":"Q000037","qualifier_name":"antagonists & inhibitors","is_major_topic":false},{"descriptor_ui":"D011687","descriptor_name":"Purines","qualifier_ui":"Q000096","qualifier_name":"biosynthesis","is_major_topic":false},{"descriptor_ui":"D013329","descriptor_name":"Structure-Activity Relationship","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D013762","descriptor_name":"Tetrahydrofolate Dehydrogenase","qualifier_ui":"Q000378","qualifier_name":"metabolism","is_major_topic":false},{"descriptor_ui":"D013940","descriptor_name":"Thymidylate Synthase","qualifier_ui":"Q000037","qualifier_name":"antagonists & inhibitors","is_major_topic":false},{"descriptor_ui":"D015195","descriptor_name":"Drug Design","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false}],"locations_count":2,"locations":[{"id":"doi:10.2174/1381612033453712","doi":"https://doi.org/10.2174/1381612033453712","is_oa":false,"landing_page_url":"https://doi.org/10.2174/1381612033453712","pdf_url":null,"source":{"id":"https://openalex.org/S55674637","display_name":"Current Pharmaceutical Design","issn_l":"1381-6128","issn":["1381-6128","1873-4286"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","jufo-1","ki-jl-1","medline","norway-1","poland-70","russia-white-list-2","vabb-shw"],"host_organization":"https://openalex.org/P4310320079","host_organization_name":"Bentham Science Publishers","host_organization_lineage":["https://openalex.org/P4310320079"],"host_organization_lineage_names":["Bentham Science Publishers"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Current Pharmaceutical Design","raw_type":"journal-article"},{"id":"pmid:14529544","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/14529544","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Current pharmaceutical design","raw_type":"Journal Article"}],"best_oa_location":null,"sustainable_development_goals":[{"score":0.9537000060081482,"id":"https://metadata.un.org/sdg/3","display_name":"Good health and well-being"}],"study_designs":[],"awards":[{"id":"https://openalex.org/G1731754422","display_name":"FOLYLPOLYGLUTAMATE SYNTHETASE IN CANCER CHEMOTHERAPY","funder_award_id":"R01CA043500","funder_id":"https://openalex.org/F4320337351","funder_display_name":"National Cancer Institute"},{"id":"https://openalex.org/G9000888465","display_name":"Roswell Park Cancer Center Support Grant","funder_award_id":"P30CA016056","funder_id":"https://openalex.org/F4320337351","funder_display_name":"National Cancer Institute"}],"funders":[{"id":"https://openalex.org/F4320337351","display_name":"National Cancer Institute","ror":"https://ror.org/040gcmg81"}],"has_content":{"grobid_xml":false,"pdf":false},"content_urls":null,"referenced_works_count":0,"referenced_works":[],"related_works":["https://openalex.org/W2085577366","https://openalex.org/W2151149299","https://openalex.org/W135674487","https://openalex.org/W2402116095","https://openalex.org/W2040301739","https://openalex.org/W4230809397","https://openalex.org/W4297882644","https://openalex.org/W1537402962","https://openalex.org/W2061706564","https://openalex.org/W4285151018"],"abstract_inverted_index":{"Antifolates":[0],"are":[1,175,194,489],"the":[2,5,15,36,62,75,102,107,114,117,127,152,167,217,266,304,341,403,430,440,452,458],"oldest":[3],"of":[4,8,14,74,79,110,116,119,121,130,141,154,159,201,216,219,223,228,251,268,270,288,290,322,329,336,340,345,351,364,405,433,443,451,454,493],"antimetabolite":[6],"class":[7,353],"anticancer":[9,18,65],"agents":[10],"and":[11,77,113,139,174,180,192,221,232,246,314,333,357,383,400,495],"were":[12,326],"one":[13,59,289,337,374,469],"first":[16,21],"modern":[17],"drugs.":[19],"The":[20],"clinically":[22],"useful":[23],"antifolate,":[24],"described":[25,464],"in":[26,39,67,86,279,297,311,315,398,424,471,483,490],"1947,":[27],"was":[28,43,104],"2,4-diamino-pteroylglutamate":[29],"(4-amino-folic":[30],"acid;":[31],"aminopterin;":[32],"AMT)":[33],"which":[34],"yielded":[35],"first-ever":[37],"remissions":[38],"childhood":[40],"leukemia.":[41],"AMT":[42],"soon":[44],"superseded":[45],"by":[46,308],"its":[47,131],"10-methyl":[48],"congener,":[49],"methotrexate":[50],"(MTX),":[51],"based":[52,105],"on":[53,106,439,447],"toxicity":[54],"considerations;":[55],"MTX":[56,142,173,224,418],"remains,":[57],"with":[58,96],"limited":[60],"exception,":[61],"only":[63,373,397,401],"antifolate":[64,156,323],"agent":[66],"clinical":[68,206,369,381,496],"use":[69,166],"to":[70,88,143,151,178,197,212,238,242,275,303,421],"this":[71,389],"date.":[72],"Because":[73],"safety":[76],"utility":[78],"MTX,":[80],"considerable":[81],"effort":[82],"has":[83,378],"been":[84,384,457,463],"invested":[85],"attempting":[87],"design":[89,103,313,317],"more":[90,467],"therapeutically":[91,301],"selective":[92],"antifolates":[93,95,461],"or":[94,272,338,478],"a":[97,411],"wider":[98],"tumor":[99,431],"spectrum.":[100],"Initially,":[101],"burgeoning":[108],"knowledge":[109,444],"folate-dependent":[111,134,253,343],"pathways":[112,254,292],"determinants":[115,124],"mechanism":[118,453],"action":[120,455],"MTX.":[122,213,309],"These":[123,147,283,486],"include":[125],"transport,":[126],"tight-binding":[128],"inhibition":[129,227,245,250,269,287,306],"target":[132],"(the":[133],"enzyme":[135,324],"dihydrofolate":[136],"reductase":[137],"(DHFR)),":[138],"metabolism":[140],"poly-gamma-glutamate":[144],"(Glu(n))":[145],"metabolites.":[146],"early":[148],"studies":[149,263],"led":[150,241],"development":[153,436],"other":[155,252,481],"DHFR":[157,239],"inhibitors":[158,325,328,335],"two":[160,319,342],"types:":[161],"(1).":[162],"\"classical\"":[163],"analogs":[164,185,203,488],"that":[165,186,193,226,265,286,465,474,479],"same":[168],"cellular":[169],"transport":[170,190],"systems":[171,191],"as":[172],"also":[176],"metabolized":[177,196],"Glu(n);":[179],"(2).":[181],"\"nonclassical\"":[182],"(i.e.,":[183],"lipophilic)":[184],"do":[187],"not":[188,195,256],"require":[189],"Glu(n).":[198],"Although":[199],"several":[200,363],"these":[202,291,365],"have":[204,366,456,462,475],"undergone":[205],"trial,":[207],"none":[208],"is":[209,394,419],"proved":[210],"superior":[211,302],"Detailed":[214],"examination":[215],"mechanisms":[218],"cytotoxicity":[220],"selectivity":[222],"showed":[225,264],"both":[229,339,355],"dTMP":[230,271],"synthesis":[231,244,274],"de":[233,346],"novo":[234,347],"purine":[235,273,348],"synthesis,":[236],"secondary":[237],"inhibition,":[240],"DNA":[243],"subsequent":[247],"cell":[248,260,276,281],"death;":[249],"did":[255],"appear":[257],"necessary":[258],"for":[259,386,402,414],"death.":[261],"Further":[262],"contribution":[267],"death":[277],"varied":[278],"different":[280],"types.":[282,359],"data":[284],"suggested":[285],"individually":[293],"might":[294],"(at":[295],"least":[296],"some":[298],"cases)":[299],"be":[300,422],"dual":[305],"induced":[307],"Thus":[310],"rational":[312],"structure-based":[316],"studies,":[318],"new":[320,375,487],"classes":[321],"elaborated-direct":[327],"thymidylate":[330],"synthase":[331],"(TMPS)":[332],"direct":[334],"enzymes":[344],"synthesis.":[349],"Members":[350],"each":[352],"included":[354],"classical":[356],"nonclassical":[358],"After":[360],"preclinical":[361,494],"evaluation,":[362],"moved":[367],"into":[368],"trials.":[370],"To":[371],"date":[372],"TMPS":[376],"inhibitor":[377],"successfully":[379],"completed":[380],"trials":[382],"approved":[385,396],"routine":[387],"use;":[388],"drug,":[390],"Tomudex":[391,428],"(D1694,":[392],"raltitrexed)":[393],"currently":[395],"Europe":[399],"treatment":[404],"colon":[406,425],"cancer.":[407],"This":[408],"still":[409],"represents":[410],"step":[412],"forward":[413],"antifolates,":[415,448],"however,":[416],"since":[417],"well-known":[420],"ineffective":[423],"cancer;":[426],"thus":[427],"extends":[429],"range":[432],"antifolates.":[434],"Antifolate":[435],"continues.":[437],"Based":[438],"immense":[441],"body":[442],"now":[445],"extant":[446],"specific":[449],"aspects":[450],"focus.":[459],"Newer":[460],"inhibit":[466,480],"than":[468],"pathway":[470],"folate":[472,484],"metabolism,":[473],"improved":[476],"delivery,":[477],"targets":[482],"metabolism.":[485],"various":[491],"stages":[492],"development.":[497]},"counts_by_year":[{"year":2026,"cited_by_count":4},{"year":2025,"cited_by_count":3},{"year":2024,"cited_by_count":8},{"year":2023,"cited_by_count":8},{"year":2022,"cited_by_count":7},{"year":2021,"cited_by_count":5},{"year":2020,"cited_by_count":13},{"year":2019,"cited_by_count":7},{"year":2018,"cited_by_count":20},{"year":2017,"cited_by_count":10},{"year":2016,"cited_by_count":13},{"year":2015,"cited_by_count":13},{"year":2014,"cited_by_count":20},{"year":2013,"cited_by_count":15},{"year":2012,"cited_by_count":12}],"updated_date":"2026-11-06T12:05:46.655746","created_date":"2016-06-24T00:00:00"}